Asset profile
XEN-D0501
Small molecule
Evidence outlook · lead readout
NCT05353686 · Efficacy, Safety, Pharmacokinetics, Diabetes Mellitus, Type 2
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05353686: The study was a randomized, triple-blind, placebo-controlled parallel-group trial involving 54 participants. Its primary endpoint was fasting blood glucose, a surrogate measure, and the outcome cannot be classified as met or missed because results are not available.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.